Terbium 161- PSMA I&T

N/A

Report date: 2026/03/04 20:01:44

NME

Base Information

Drug NameTerbium 161- PSMA I&T

Drug Alias NameN/A

ClassificationRadiation-emitting products > Radionuclide Drug ConjugatesSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)Radiation-emitting products > Nuclides > Terbium > 161Tb +[4]

Mechanisms of ActionProstate-Specific Membrane Antigen binders

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesOncosia Scientific GmbH

China Registration ClassN/A

Develop Information

Active CompaniesOncosia Scientific GmbH Ankara University

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A